Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high price tag
and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy. In this video Director Sue Marett discusses the opportunities and challenges for new immuno-oncology therapies and outlines what these mean for pharma market research.
http://www.researchpartnership.com/news/2016/05/video-immuno-oncology-therapies/